Recent Finacing
Recent Raise
PRISM BioLab develops oral small‑molecule inhibitors of protein–protein interactions using proprietary PepMetics scaffolds that mimic alpha‑helix and beta‑turn structures, combined with AI‑supported design and pharma collaborations.
